{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T05:53:09Z","timestamp":1782885189399,"version":"3.54.5"},"reference-count":14,"publisher":"Oceanside Publications Inc.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"\n Background:<\/jats:bold>\n Chronic spontaneous urticaria (CSU) significantly impairs patient quality of life (QoL) through recurrent wheals and pruritus. The urticaria activity score over 7 days (UAS7) and the chronic urticaria quality of life questionnaire (CU-Q2oL) are validated patient-reported\n outcome measures recommended by international guidelines for monitoring CSU. Whether these two measures track in parallel over a structured treatment course, particularly as disease activity diminishes, remains incompletely characterized, especially in South Asian populations.\n Methods:<\/jats:bold>\n A 6-month prospective observational study was conducted at a tertiary-care dermatology center in India. Fifty adult patients with active CSU were enrolled. All received second-generation H1-antihistamines (cetirizine, levocetirizine, or fexofenadine) with dose up-titration up to fourfold\n as needed per international urticaria guideline recommendations guideline recommendations. No patients required omalizumab during the study period. The UAS7 and CU-Q2oL scores were recorded at baseline and monthly for 6 months. Baseline total serum immunoglobulin E (IgE) values and absolute\n eosinophil counts (AEC) were correlated with the clinical scores. Statistical analysis included Wilcoxon signed rank tests for longitudinal change and the Spearman rank correlation at each time point. The sample size was based on clinical feasibility; the study is considered exploratory.\n Results:<\/jats:bold>\n The mean \u00b1 standard deviation baseline UAS7 score was 30.3 \u00b1 9.1 (severe disease), and the mean \u00b1 standard deviation CU-Q2oL score was 51.4 \u00b1 13.2. Both scores improved significantly by 6 months (UAS7 score: 5.1; CU-Q2oL score: 12.5; p\u2009<\u20090.0001\n for both). The UAS7\u2010CU-Q2oL correlation was moderate when the disease was active (Spearman r = 0.44, p\u2009=\u20090.002 at 1 month) but weakened substantially as disease activity declined (r \u2248 0.25, p\u2009=\u20090.08 at 3 months; r \u2248 0.08, p\u2009>\u20090.5\n at 6 months). Baseline total IgE value and AEC did not correlate with disease severity or QoL at any time point.\n Conclusion:<\/jats:bold>\n UAS7 and CU-Q2oL scores correlate during active CSU but diverge as disease is controlled. Even after symptom resolution, some patients retain residual\n QoL impairment. Routine use of both measures is recommended because UAS7 alone may underestimate the patient burden during remission. The total IgE value and AEC are not reliable surrogate markers of CSU severity or QoL in this exploratory cohort.\n <\/jats:p>","DOI":"10.2500\/aap.2026.47.260027","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T04:30:30Z","timestamp":1782361830000},"page":"e57-e64","source":"Crossref","is-referenced-by-count":1,"title":["Correlation of disease activity (Urticaria Activity Score over 7 Days) and quality of life (Chronic Urticaria Quality of Life Questionnaire) in patients with chronic spontaneous urticaria: A prospective observational study"],"prefix":"10.2500","volume":"47","author":[{"given":"Mahashweta","family":"Dash","sequence":"first","affiliation":[{"name":"From the Department of Dermatology, Command Hospital, Pune, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afreen","family":"Ayub","sequence":"additional","affiliation":[{"name":"Department of Dermatology, INHS Asvini, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biju","family":"Vasudevan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Command Hospital, Chandimandir, India; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aradhana","family":"Sood","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Manipal Hospital, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1111\/1346-8138.17943","article-title":"Prevalence, comorbidities, and current management of chronic spontaneous urticaria in Japan: retrospective claims database study","volume":"52","author":"Fukunaga","year":"2025","journal-title":"J Dermatol"},{"key":"B2","doi-asserted-by":"crossref","first-page":"7482","DOI":"10.3390\/jcm12237482","article-title":"Epidemiological and clinical characteristics of adult and pediatric patients with chronic spontaneous urticaria","volume":"12","author":"Barzilai","year":"2023","journal-title":"J Clin Med"},{"key":"B3","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"key":"B4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13223-015-0072-2","article-title":"Insights and advances in chronic urticaria: a Canadian perspective","volume":"11","author":"Sussman","year":"2015","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B5","doi-asserted-by":"crossref","first-page":"385","DOI":"10.25259\/IJDVL_1059_2021","article-title":"Adaptation and validation of the Bengali version of the chronic urticaria quality of life questionnaire (CU-Q2oL)","volume":"89","author":"Dhabal","year":"2023","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"B6","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.jaci.2022.04.010","article-title":"Autoimmune chronic spontaneous urticaria","volume":"149","author":"Kolkhir","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B7","doi-asserted-by":"crossref","first-page":"206","DOI":"10.4168\/aair.2021.13.2.206","article-title":"Total IgE as a marker for chronic spontaneous urticaria","volume":"13","author":"Altrichter","year":"2021","journal-title":"Allergy Asthma Immunol Res"},{"key":"B8","doi-asserted-by":"crossref","first-page":"e0317499","DOI":"10.1371\/journal.pone.0317499","article-title":"Factors associated with quality of life of chronic spontaneous urticaria patients in a Vietnamese population","volume":"20","author":"My","year":"2025","journal-title":"PLoS One"},{"key":"B9","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00403-021-02300-4","article-title":"Chinese version of the chronic urticaria quality of life questionnaire: cultural adaptation, factor analysis, assessment of reliability and validity","volume":"314","author":"Zhao","year":"2022","journal-title":"Arch Dermatol Res"},{"key":"B10","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1016\/j.jaip.2025.05.033","article-title":"Parameters linked with higher itch severity in chronic spontaneous urticaria \u2014 Chronic Urticaria Registry results","volume":"13","author":"Stolz","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B11","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/jdv.16947","article-title":"The Chronic Urticaria Registry: rationale, methods and initial implementation","volume":"35","author":"Weller","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B12","doi-asserted-by":"crossref","first-page":"e70026","DOI":"10.1002\/clt2.70026","article-title":"Disease control and quality of life in chronic spontaneous urticaria and recurrent angioedema are strongly linked, but not in all patients","volume":"15","author":"Neisinger","year":"2025","journal-title":"Clin Transl Allergy"},{"key":"B13","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000314370","article-title":"Elevated serum total IgE: a potential marker for severe chronic urticaria","volume":"153","author":"Kessel","year":"2010","journal-title":"Int Arch Allergy Immunol"},{"key":"B14","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1111\/all.13949","article-title":"Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: results of the PURIST study","volume":"74","author":"Schoepke","year":"2019","journal-title":"Allergy"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2026\/00000047\/00000004\/art00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T04:36:53Z","timestamp":1782880613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2026.47.260027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7,1]]}},"alternative-id":["1088-5412(20260701)47:4L.57;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2026.47.260027","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}